Results 31 to 40 of about 655,529 (373)

One Bout of Aerobic Exercise Can Enhance the Expression of Nr1d1 in Oxidative Skeletal Muscle Samples

open access: yesFrontiers in Physiology, 2021
The nuclear receptor subfamily 1, group D member 1 (Nr1d1), plays a role in the skeletal muscle’s oxidative capacity, mitochondrial biogenesis, atrophy genes, and muscle fiber size.
Rafael L. Rovina   +8 more
doaj   +1 more source

Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy

open access: yesCells, 2020
Insulin-like growth factor-1 (IGF-1) is a key growth factor that regulates both anabolic and catabolic pathways in skeletal muscle. IGF-1 increases skeletal muscle protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3β pathways. PI3K/Akt can also inhibit
Tadashi Yoshida, P. Delafontaine
semanticscholar   +1 more source

Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy

open access: yesNature Communications, 2021
The thrombospondin (Thbs) family of secreted matricellular proteins are stress- and injury-induced mediators of cellular attachment dynamics and extracellular matrix protein production.
D. Vanhoutte   +8 more
semanticscholar   +1 more source

Dominant optic atrophy [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2012
DEFINITION OF THE DISEASE: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the
Dominique Bonneau   +11 more
openaire   +7 more sources

The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis

open access: yesFrontiers in Neurology, 2017
IntroductionMultiple sclerosis (MS) is characterised by the accumulation of permanent neurological disability secondary to irreversible tissue loss (neurodegeneration) in the brain and spinal cord.
Maria A. Rocca   +4 more
doaj   +1 more source

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

open access: yesEfficacy and Mechanism Evaluation, 2020
Background: Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis.
Floriana De Angelis   +27 more
doaj   +1 more source

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

open access: yesScience Translational Medicine, 2020
Tau imaging with [18F]flortaucipir predicts the severity and topography of subsequent MRI cortical atrophy in patients with Alzheimer’s disease. Predictive PET Understanding the dynamic of the two major hallmark of Alzheimer’s disease (AD), tau protein ...
R. La Joie   +21 more
semanticscholar   +1 more source

Botulinum Toxin Induced Atrophy: An Uncharted Territory

open access: yesToxins, 2018
Botulinum neurotoxins (BoNTs) produce local chemo-denervation by cleaving soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins.
Mehri Salari   +2 more
doaj   +1 more source

LGMD D2 TNPO3-Related: From Clinical Spectrum to Pathogenetic Mechanism

open access: yesFrontiers in Neurology, 2022
Limb-girdle muscular dystrophies (LGMDs) are clinically and genetically heterogeneous diseases presenting with a wide clinical spectrum. Autosomal dominant LGMDs represent about 10–15% of LGMDs and include disorders due to defects of DNAJB6, transportin ...
Roberta Costa   +8 more
doaj   +1 more source

The use of mesenchymal stem cells in optic nerve atrophy in patients with multiple sclerosis: A pilot study

open access: yesАнналы клинической и экспериментальной неврологии, 2017
Introduction. Cellular therapy of multiple sclerosis is currently considered to be one of the most promising treatment alternatives for this severe pathology of the nervous system. Materials and Methods.
Gennadiy N. Bisaga   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy